SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Benjamin P. Sinder, William R. Lloyd, Joseph D. Salemi, Joan C. Marini, Michelle S. Caird, Michael D. Morris, Kenneth M. Kozloff, Effect of anti-sclerostin therapy and osteogenesis imperfecta on tissue-level properties in growing and adult mice while controlling for tissue age, Bone, 2016, 84, 222

    CrossRef

  2. 2
    Natasha M. Appelman-Dijkstra, Socrates E. Papapoulos, From disease to treatment: from rare skeletal disorders to treatments for osteoporosis, Endocrine, 2016,

    CrossRef

  3. 3
    Natasha M. Appelman-Dijkstra, Socrates E. Papapoulos, Sclerostin Inhibition in the Management of Osteoporosis, Calcified Tissue International, 2016, 98, 4, 370

    CrossRef

  4. 4
    W. Yao, W. Dai, L. Jiang, E. Y.-A. Lay, Z. Zhong, R. O. Ritchie, X. Li, H. Ke, N. E. Lane, Sclerostin-antibody treatment of glucocorticoid-induced osteoporosis maintained bone mass and strength, Osteoporosis International, 2016, 27, 1, 283

    CrossRef

  5. 5
    E. Cavalier, P. Bergmann, O. Bruyère, P. Delanaye, A. Durnez, J.-P. Devogelaer, S. L. Ferrari, E. Gielen, S. Goemaere, J.-M. Kaufman, A. Nzeusseu Toukap, J.-Y. Reginster, A.-F. Rousseau, S. Rozenberg, A. J. Scheen, J.-J. Body, The role of biochemical of bone turnover markers in osteoporosis and metabolic bone disease: a consensus paper of the Belgian Bone Club, Osteoporosis International, 2016,

    CrossRef

  6. 6
    Robert L. Jilka, Charles A. O’Brien, The Role of Osteocytes in Age-Related Bone Loss, Current Osteoporosis Reports, 2016, 14, 1, 16

    CrossRef

  7. 7
    Natalie A. Sims, T. John Martin, Julian M.W. Quinn, Osteoimmunology, 2016,

    CrossRef

  8. 8
    Michael S. Ominsky, Danielle L. Brown, Gwyneth Van, David Cordover, Efrain Pacheco, Emily Frazier, Linda Cherepow, Marnie Higgins-Garn, J. Ignacio Aguirre, Thomas J. Wronski, Marina Stolina, Lei Zhou, Ian Pyrah, Rogely Waite Boyce, Differential temporal effects of sclerostin antibody and parathyroid hormone on cancellous and cortical bone and quantitative differences in effects on the osteoblast lineage in young intact rats, Bone, 2015, 81, 380

    CrossRef

  9. 9
    Juliet Compston, Emerging therapeutic concepts for muscle and bone preservation/building, Bone, 2015, 80, 150

    CrossRef

  10. 10
    Robert Brommage, Genetic Approaches To Identifying Novel Osteoporosis Drug Targets, Journal of Cellular Biochemistry, 2015, 116, 10
  11. 11
    Reinhold G. Erben, Hypothesis: Coupling between Resorption and Formation in Cancellous bone Remodeling is a Mechanically Controlled Event, Frontiers in Endocrinology, 2015, 6,

    CrossRef

  12. 12
    Natasha M. Appelman-Dijkstra, Socrates E. Papapoulos, Modulating Bone Resorption and Bone Formation in Opposite Directions in the Treatment of Postmenopausal Osteoporosis, Drugs, 2015, 75, 10, 1049

    CrossRef

  13. 13
    Bente L. Langdahl, New treatments of osteoporosis, Osteoporosis and Sarcopenia, 2015, 1, 1, 4

    CrossRef

  14. 14
    Kim Henriksen, Christian Schneider Thudium, Claus Christiansen, Morten Asser Karsdal, Novel targets for the prevention of osteoporosis – lessons learned from studies of metabolic bone disorders, Expert Opinion on Therapeutic Targets, 2015, 19, 11, 1575

    CrossRef

  15. 15
    T. Sugiyama, Y. T. Kim, H. Oda, Osteoporosis therapy: a novel insight from natural homeostatic system in the skeleton, Osteoporosis International, 2015, 26, 2, 443

    CrossRef

  16. 16
    Hui Chen, Xinchen Xu, Min Liu, Wen Zhang, Hua-zhu Ke, An Qin, Tingting Tang, Eryi Lu, Sclerostin antibody treatment causes greater alveolar crest height and bone mass in an ovariectomized rat model of localized periodontitis, Bone, 2015, 76, 141

    CrossRef

  17. 17
    Paul Nioi, Scott Taylor, Rong Hu, Efrain Pacheco, Yudong D He, Hisham Hamadeh, Chris Paszty, Ian Pyrah, Michael S Ominsky, Rogely Waite Boyce, Transcriptional Profiling of Laser Capture Microdissected Subpopulations of the Osteoblast Lineage Provides Insight Into the Early Response to Sclerostin Antibody in Rats, Journal of Bone and Mineral Research, 2015, 30, 8
  18. 18
    Socrates E. Papapoulos, Anabolic bone therapies in 2014: New bone-forming treatments for osteoporosis, Nature Reviews Endocrinology, 2014, 11, 2, 69

    CrossRef

  19. 19
    Serge Ferrari, Future directions for new medical entities in osteoporosis, Best Practice & Research Clinical Endocrinology & Metabolism, 2014, 28, 6, 859

    CrossRef

  20. 20
    R. Sapir-Koren, G. Livshits, Osteocyte control of bone remodeling: is sclerostin a key molecular coordinator of the balanced bone resorption–formation cycles?, Osteoporosis International, 2014, 25, 12, 2685

    CrossRef